Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness–adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension.
In: Osteoporosis International, Jg. 34 (2023-06-01), Heft 6, S. 1075-1084
Online
academicJournal
Zugriff:
Summary: In postmenopausal women with osteoporosis, up to 10 years of denosumab treatment significantly and continuously improved bone microarchitecture assessed by tissue thickness–adjusted trabecular bone score, independently of bone mineral density. Long-term denosumab treatment decreased the number of high fracture-risk patients and shifted more patients to lower fracture-risk categories. Purpose: To investigate the long-term effect of denosumab on bone microarchitecture assessed by tissue thickness–adjusted trabecular bone score (TBS TT ) in post-hoc subgroup analysis of FREEDOM and open-label extension (OLE). Methods: Postmenopausal women with lumbar spine (LS) or total hip BMD T-score <−2.5 and ≥−4.0 who completed the FREEDOM DXA substudy and continued in OLE were included. Patients received either denosumab 60 mg subcutaneously every 6 months for 3 years and same-dose open-label denosumab for 7 years (long-term denosumab; n=150) or placebo for 3 years and open-label denosumab for 7 years (crossover denosumab; n=129). BMD and TBS TT were assessed on LS DXA scans at FREEDOM baseline, month 1, and years 1–6, 8, and 10. Results: In long-term denosumab group, continued increases from baseline to years 4, 5, 6, 8, and 10 in BMD (11.6%, 13.7%, 15.5%, 18.5%, and 22.4%) and TBS TT (3.2%, 2.9%, 4.1%, 3.6%, and 4.7%) were observed (all P < 0.0001). Long-term denosumab treatment decreased the proportion of patients at high fracture-risk (according to TBS TT and BMD T-score) from baseline up to year 10 (93.7 to 40.4%), resulting in increases in the proportions at medium-risk (6.3 to 53.9%) and low-risk (0 to 5.7%) (P < 0.0001). Similar responses were observed in crossover denosumab group. Changes in BMD and TBS TT were poorly correlated during denosumab treatment. Conclusion: In postmenopausal women with osteoporosis, up to 10 years of denosumab significantly and continuously improved bone microarchitecture assessed by TBS TT , independently of BMD, and shifted more patients to lower fracture-risk categories. [ABSTRACT FROM AUTHOR]
Copyright of Osteoporosis International is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness–adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension.
|
---|---|
Autor/in / Beteiligte Person: | Hans, Didier ; McDermott, Michele ; Huang, Shuang ; Kim, Min ; Shevroja, Enisa ; McClung, Michael |
Link: | |
Zeitschrift: | Osteoporosis International, Jg. 34 (2023-06-01), Heft 6, S. 1075-1084 |
Veröffentlichung: | 2023 |
Medientyp: | academicJournal |
ISSN: | 0937-941X (print) |
DOI: | 10.1007/s00198-023-06708-8 |
Schlagwort: |
|
Sonstiges: |
|